Silencing of 4E-BP1 using specific siRNA (si4E-BP1) (Fig2F) circumvented the inhibitory effects of SOM230 on CAF protein synthesis (Fig2G) and on CAF-CM-dependent protection against gemcitabine-triggered cancer cell viability (Fig2H) and apoptosis (Fig2I). The gene discussed is EIF4EBP1; the disease is cancer.